PT  - JOURNAL ARTICLE
AU  - Michael Kreuter
AU  - Hans-Joachim Kabitz
AU  - Lars Hagmeyer
AU  - Peter Hammerl
AU  - Albert Esselmann
AU  - Conrad Wiederhold
AU  - Dirk Skowasch
AU  - Christoph Stolpe
AU  - Marcus Joest
AU  - Stefan Veitshans
AU  - Phillen Maqhuzu
AU  - Larissa Schwarzkopf
AU  - Andreas Hellmann
AU  - Michael Pfeifer
AU  - Jürgen Behr
AU  - Dagmar Kauschka
AU  - Andreas Günther
AU  - Felix J. F. Herth
AU  - Philipp Markart
TI  - Treatment and survival diversities in different forms of ILD in Germany - EXCITING registry
AID  - 10.1183/13993003.congress-2019.PA4725
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA4725
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/PA4725.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/PA4725.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Background: Real life data on outcome and treatment diversities in different ILD are scant.Method: We analysed prospective data from the German EXCITING registry of consecutive ILD patients in 37 pulmonology centres.Results: Out of 601 patients (60% male, medians: age 64 years, FVC 75%, DLCO 53%), 40% had idiopathic forms (IIP), 28% sarcoidosis, 10% hypersensitivity pneumonitis (HP) and 7% CTD-ILD. At baseline, IIPs were mainly treated with antifibrotic drugs (66%), but also received prednisolone in 49%. Sarcoidosis, HP and CTD-ILD mainly received steroids (85%, 98% and 81%) and rarely other immunosuppressants (azathioprine 12%, 27%, 34%; MTX 15%, 9%, 9%). Non-pharmacological treatments were sparse and did not increase over time: pulmonary rehabilitation at baseline (base) and during follow up (FU) 4%, LTOT at base 18%, increase to 21%, and NIV 4% at base and during FU. Only 3 patients received LTX. At base, 48% (n=288) were hospitalised, in 94% due to ILD, mainly for diagnostic procedures (72%) and rarely for other reasons (pneumonia 12%, AE-ILD 16%). After 6 and 12 months, hospitalisations decreased (n=127) with less frequent ILD association (72% after 6, 42% after 12 months). Yet, non-elective hospitalisations increased (at 6 and 12 months: infections 33% and 30%, AE-ILD 15% and 23%) over time. Mean overall survival by Kaplan-Meier estimates (total cohort 168 months (± 6)) differed in patients between IIP, sarcoidosis and HP with 107 months (±7), 225 (± 6.8), and 166 months (± 18).Conclusions: ILDs differ substantial in treatment forms and outcomes. Notably, non-pharmacological treatments are mainly neglected and despite a high rate of severe ILDs only 3 LTX were performed.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4725.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).